Business Context and Reporting Period
Company: Delcath Systems, Inc.
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2010
Business Stage: Development Stage Company
Core Business: Delcath is developing the Delcath Percutaneous Hepatic Perfusion (PHP) System, an investigational medical device and drug combination (melphalan) designed to treat unresectable hepatic malignancies. The system is not yet approved by the FDA or any foreign regulatory agency. The company has no commercial revenues and relies on equity financing and strategic agreements to fund operations.
Key Financial Metrics
| Metric | Q1 2010 | Q1 2009 | Cumulative (Inception to Mar 31, 2010) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Total Costs & Expenses | $5,487,282 | $1,936,153 | $71,199,552 |
| Operating Loss | $(5,487,282) | $(1,936,153) | $(71,199,552) |
| Net Loss | $(14,173,735) | $(2,445,481) | $(82,046,885) |
| Loss Per Share (Basic/Diluted) | $(0.39) | $(0.10) | N/A |
| Cash & Cash Equivalents (End of Period) | $26,933,593 | $4,804,142 | N/A |
| Short-Term Investments (CDs) | $3,235,000 | $0 | N/A |
| Total Current Liabilities | $21,160,950 | N/A | N/A |
| Warrant Liability (Current) | $19,894,931 | N/A | N/A |
| Accumulated Deficit | $(83,545,490) | N/A | N/A |
Material Changes vs. Prior Period
- Net Loss Expansion: Net loss increased by approximately $11.7 million to $14.2 million compared to $2.4 million in Q1 2009.
- Derivative Liability Impact: The primary driver of the increased loss was an $8.7 million non-cash expense related to the change in fair value of warrant liabilities (mark-to-market adjustments).
- Operating Expenses: Total costs and expenses rose by $3.6 million (183% increase).
- General & Administrative (G&A): Increased by $2.0 million to $2.5 million, driven by hiring in Marketing, Sales, Finance, and Manufacturing to prepare for commercialization.
- Research & Development (R&D): Increased by $1.4 million (101%) to $2.9 million, due to expanded R&D and Regulatory departments and FDA submission preparations.
- Liquidity: Cash and cash equivalents decreased by $8.6 million during the quarter due to operating cash burn of $5.1 million and investing outflows of $3.7 million (primarily purchase of CDs and equipment).
- Deferred Revenue: Recognized $300,000 in deferred revenue from a new distribution agreement, a new line item not present in the prior period.
Guidance, Outlook, and Risks
- Clinical Progress: The company recently announced (subsequent to period end) that its Phase III trial met its primary endpoint for extended hepatic progression-free survival in melanoma patients. A multi-arm Phase II trial is ongoing.
- Capital Resources: Management believes current cash resources ($26.9 million) are sufficient to fund operations through 2010. However, the company expects to continue incurring significant losses and will require additional capital for FDA submission, manufacturing, and commercialization.
- Financing: The company filed a Form S-3 registration statement (effective April 13, 2010) to raise up to $100 million in securities for general corporate purposes.
- Strategic Agreements:
- Entered a Research and Distribution Agreement with Chi-Fu Trading Co., Ltd. for Taiwan/Singapore, receiving $300,000 upfront (deferred revenue) with potential milestone payments totaling $1 million.
- Amended supply agreement with B. Braun Medical Inc. for catheter manufacturing.
- Risks:
- Regulatory: No FDA approval; failure to obtain approval would materially adversely affect the business.
- Financial: Significant accumulated deficit ($83.5 million); dependence on equity financing; volatility in warrant liability valuation impacting net income.
- Development: Uncertainty regarding timelines and costs of clinical trials and regulatory filings.
Investor Verification Checklist
- Warrant Liability Volatility: Verify the sensitivity of the $19.9 million warrant liability to changes in stock price and volatility, as this creates significant non-cash losses that obscure operating performance.
- Cash Burn Rate: Confirm the sustainability of the ~$5 million quarterly operating cash burn against the $26.9 million cash balance to validate the "sufficient through 2010" guidance.
- Phase III Data: Review the independent analysis of the Phase III trial results announced in April 2010 to assess the probability of FDA approval.
- Deferred Revenue Recognition: Monitor the amortization schedule of the $300,000 deferred revenue from the Chi-Fu agreement and the conditions for the remaining $700,000 in milestone payments.
- Equity Dilution: Assess the potential dilution from the $100 million shelf registration (Form S-3) and the outstanding 3.4 million stock options and 3.4 million warrants.